~~<i id='AE0B897530'><strike id='AE0B897530'><tt id='AE0B897530'><pre id='AE0B897530'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

focus

author：explore 2025-09-30 06:09:14 - browse：1

JOHNSON & JOHNSON HEADQUARTERS — Daniel Hulshizer/AP

Eight months into his tenure, Johnson & Johnson’s R&D chief is putting a big emphasis on medicines for cancer, treatment-resistant depression, and autoimmune disease.

To sharpen that focus, R&D chief John Reed told STAT that the company is de-emphasizing two areas that have been mainstays for the drug and medical device giant: infectious disease and vaccines, as well as medicines targeting kidney disease and rare eye conditions.

The disclosures were made in an interview ahead of an investor meeting Reed is leading Tuesday aimed at generating excitement about the company’s research and development efforts.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Change Healthcare can notify patients about the breach, HHS says

hotspot

knowledge

hotspot

entertainment

leisure time

hotspot

RichardPazdur,right,alsospokeabouttheFDA'suseofacceleratedapproval.MeganBearderPhotographyCHICAGO— T

WSS

Ionis drug prevents swelling attacks due to hereditary angioedema

Election results set back Medicaid expansion plans

Failure, not just success, should guide future doctors

Failure, not just success, should guide future doctors

BMI, flaws aside, is found to be useful estimate of body fat in youth

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

leisure time

focus

hotspot

In Memoriam: Notable people who died in 2023

Failure, not just success, should guide future doctors

State Dept. review finds Biden bears some blame for Afghanistan failures

It was time to plan for my old age. If only I could stop crying

FDA approval of Sarepta Duchenne genetic therapy gives me hope

A fugitive mob suspect in Greece is betrayed by his passion for hometown Naples soccer champions

How one medical school became remarkably diverse

See how much Covid

Novavax promises a turnaround & Lilly roils the obesity market

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

knowledge

ASCO: AstraZeneca says CAR

Kaiser's Risant Health gobbled up Geisinger. Who is next?

ASCO: Palliative care found as helpful given virtually as in person

Many breast cancer patients receive more radiation than needed

BMI, flaws aside, is found to be useful estimate of body fat in youth

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

hotspot

entertainment

leisure time

hotspot